The successful clinical trials of PI3k/Akt inhibitors and cell cycle inhibitors in breast cancer management strongly support our suggestion that targeting the PI3K/Akt/FoxO axis can induce cell cycle arrest, highlighting its translational potential in cancer treatment. The gene discussed is AKT1; the disease is cancer.